We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that...
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid...
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan...
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in...
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of...
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 7.1 | 39.4444444444 | 18 | 25.715 | 15.2 | 1164601 | 17.42942118 | CS |
| 4 | 8.07 | 47.3869641809 | 17.03 | 25.715 | 15.2 | 742193 | 17.38810095 | CS |
| 12 | 7.62 | 43.5926773455 | 17.48 | 25.715 | 14.98 | 563057 | 17.39482014 | CS |
| 26 | 16.52 | 192.540792541 | 8.58 | 25.715 | 7.64 | 393237 | 15.14613473 | CS |
| 52 | 14.7 | 141.346153846 | 10.4 | 25.715 | 7.64 | 318167 | 13.46474283 | CS |
| 156 | -6.52 | -20.6198608476 | 31.62 | 37.6 | 7.3 | 277859 | 14.96829626 | CS |
| 260 | -16.9 | -40.2380952381 | 42 | 59.85 | 7.3 | 279678 | 17.34635728 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
